The Tumor BRACAnalysis CDx brand, founded in 2015 (United States), from 28 sister brands and 2617 competing brands. Tumor BRACAnalysis CDx is a brand of Myriad Genetics, listed on the stock exchange of New York. Tumor BRACAnalysis CDx belongs to the Medical Diagnostics & Research business sector.
Share price and profitability of the share Myriad Genetics (Tumor BRACAnalysis CDx)
Buy Myriad Genetics share with
(0% commission and fractional shares)
Your capital is subject to risk. Other fees apply. For more information, visit etoro.com/trading/fees.
Investment simulator :
Portfolio valuation
Myriad Genetics
(Tumor BRACAnalysis CDx)
over 5 years*
USD 10.29
Stock market history Myriad Genetics (Tumor BRACAnalysis CDx)
*non inclusive of dividends, non inclusive of market orders
past performances do not prejudice future performances
past performances do not prejudice future performances
